Literature DB >> 19359270

Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis.

A G Richter1, R A Stockley, L Harper, D R Thickett.   

Abstract

RATIONALE: Wegener granulomatosis (WG) has previously been associated with increased nasal carriage of Staphylococcus aureus, but no studies have investigated the occurrence of pathogen growth in the lower airways.
OBJECTIVES: To culture bronchoalveolar lavage fluid (BALF) from patients with WG, patients with idiopathic pulmonary fibrosis (IPF) and normal controls.
METHODS: 33 patients with WG, 22 with IPF and 8 normal controls underwent bronchoscopy and bronchoalveolar lavage. Quantitative culture established bacterial levels in the lower airways. Culture experiments were designed to investigate whether BALF is a supportive environment for S aureus growth. BALF cytokines were measured by ELISA.
RESULTS: Pathogens were commonly grown from BALF of patients with WG and those with IPF. S aureus was particularly associated with patients with WG both in relapse and in remission. BALF levels of interleukin 1 receptor antagonist (IL1ra) were statistically significantly elevated in those patients who grew a pathogen from lavage fluid. BALF from patients with WG and IPF stimulated S aureus growth compared with normal lavage fluid.
CONCLUSIONS: Pathogens are more commonly isolated from BALF from patients with WG than from that of patients with IPF or normal controls, and with a different culture profile. IL1ra was associated with pathogen growth in WG and IPF. WG BALF is a trophic environment for S aureus growth. Pulmonologists treating patients with acute or relapsing WG should consider bronchoscopic microbiological sampling and consider antibiotics with antistaphylococcal activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19359270     DOI: 10.1136/thx.2008.110445

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

Review 1.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

2.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.

Authors:  MeiLan K Han; Yueren Zhou; Susan Murray; Nabihah Tayob; Imre Noth; Vibha N Lama; Bethany B Moore; Eric S White; Kevin R Flaherty; Gary B Huffnagle; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2014-04-21       Impact factor: 30.700

Review 3.  The respiratory microbiome in idiopathic pulmonary fibrosis.

Authors:  Richard J Hewitt; Philip L Molyneaux
Journal:  Ann Transl Med       Date:  2017-06

Review 4.  Plasma membrane wounding and repair in pulmonary diseases.

Authors:  Xiaofei Cong; Rolf D Hubmayr; Changgong Li; Xiaoli Zhao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-06       Impact factor: 5.464

5.  Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.

Authors:  Andrew M Wilson; Allan B Clark; Tony Cahn; Edwin R Chilvers; William Fraser; Matthew Hammond; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David R Thickett; Moira Whyte
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

Review 6.  Microbiome in interstitial lung disease: from pathogenesis to treatment target.

Authors:  Margaret L Salisbury; MeiLan K Han; Robert P Dickson; Philip L Molyneaux
Journal:  Curr Opin Pulm Med       Date:  2017-09       Impact factor: 3.155

Review 7.  Pulmonary vasculitis: clinical presentation, differential diagnosis, and management.

Authors:  Jennifer Ramsey; Mohammed Amari; Stephen P Kantrow
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

8.  Essential role of IL-17 in acute exacerbation of pulmonary fibrosis induced by non-typeable Haemophilus influenzae.

Authors:  Shengsen Chen; Xinyun Zhang; Cheng Yang; Shi Wang; Hao Shen
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

Review 9.  The evolving role of the lung microbiome in pulmonary fibrosis.

Authors:  Jay H Lipinski; Bethany B Moore; David N O'Dwyer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-02       Impact factor: 5.464

10.  Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis.

Authors:  Janet Wohlers; Katrin Breucker; Rainer Podschun; Jürgen Hedderich; Peter Lamprecht; Petra Ambrosch; Martin Laudien
Journal:  Arthritis Res Ther       Date:  2012-10-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.